Tarsus officer to sell $800K in stock in 2026
Rhea-AI Filing Summary
Tarsus Pharmaceuticals, Inc. (TARS) received a notice that officer Bobak Azamian, through the Bobak Azamian Living Trust, intends to sell 10,000 shares of common stock under Rule 144, with an indicated aggregate market value of $800,568.71, through Merrill Lynch on NASDAQ.
The shares to be sold were originally acquired on January 13, 2017 in a private placement. In the preceding three months, the Bobak Azamian Living Trust sold an additional 10,000 shares of Tarsus common stock on June 17, 2026 for proceeds of $615,473.27.
Positive
- None.
Negative
- None.
Key Figures
Shares to be sold under Rule 144: 10,000 shares
Aggregate market value of proposed sale: $800,568.71
Shares sold in past 3 months: 10,000 shares
+3 more
6 metrics
Shares to be sold under Rule 144
10,000 shares
Common stock of Tarsus Pharmaceuticals, Inc. to be sold by the Bobak Azamian Living Trust
Aggregate market value of proposed sale
$800,568.71
Value of 10,000 TARS shares indicated in the Rule 144 notice
Shares sold in past 3 months
10,000 shares
Common stock sold by the Bobak Azamian Living Trust on June 17, 2026
Proceeds from past 3‑month sale
$615,473.27
Total proceeds from 10,000 TARS shares sold on June 17, 2026
Acquisition date of shares to be sold
January 13, 2017
Original acquisition date in a private placement
Planned sale date reference
September 2, 2026
Date associated with the securities information and notice
Key Terms
Rule 144, private placement, aggregate market value, Form 144, +1 more
5 terms
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
private placement financial
"COMMON | 01/13/2017 | PRIVATE PLACEMENT | TARSUS PHARMACEUTICALS INC"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
aggregate market value financial
"| 10000 | 800568.71 | 43882996 | 09/02/2026 | NASDAQ"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.
Form 144 regulatory
"144: Filer Information"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
Living Trust financial
"BOBAK AZAMIAN LIVING TRUST 17700 LAGUNA CANYON ROAD FL 4 IRVINE CA 92618"
FAQ
What does the Form 144 filing disclose for TARS?
The filing states that 10,000 shares of Tarsus Pharmaceuticals, Inc. (TARS) common stock held in the Bobak Azamian Living Trust are intended to be sold under Rule 144, with an indicated $800,568.71 aggregate market value through Merrill Lynch on NASDAQ.
AI-generated analysis. How Rhea-AI works. Not financial advice.
